DS
TERN

David Shaw’s Terns Pharmaceuticals TERN Stock Holding History

David Shaw’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-201,191
Closed -$10.6M – 5216
2026
Q1 		$10.6M Sell
201,191
-952,838
-83% -$39.1M 0.01% 1585
2025
Q4 		$46.6M Buy
+1,154,029
New +$26.7M 0.03% 750
2025
Q1 		– Sell
-57,341
Closed -$318K – 4743
2024
Q4 		$318K Buy
57,341
+19,870
+53% +$135K ﹤0.01% 3860
2024
Q3 		$313K Buy
37,471
+10,506
+39% +$86.4K ﹤0.01% 3959
2024
Q2 		$184K Buy
26,965
+9,175
+52% +$55.6K ﹤0.01% 4090
2024
Q1 		$117K Buy
+17,790
New +$116K ﹤0.01% 3994
2023
Q2 		– Sell
-46,762
Closed -$554K – 4547
2023
Q1 		$554K Buy
+46,762
New +$447K ﹤0.01% 3510

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

David Shaw's TERN Position: Q2 2026 in Review

David Shaw sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 201,191 shares — an estimated $10.6M sold.

David Shaw first reported a position in TERN in Q1 2023 and held it in 7 quarters. The position peaked at $46.6M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • David Shaw reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • David Shaw sold 201,191 Terns Pharmaceuticals shares in Q2 2026, an estimated $10.6M.
  • David Shaw first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • David Shaw's Terns Pharmaceuticals position peaked at $46.6M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.